

estoppel as to equivalents. A marked version of the amended portions of the application is set forth in the accompanying Appendix:

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

- Sub B*
Sub B1
9. A retroviral vector according to claim 9 which comprises at least one component from an equine lentivirus.
- Sub C1*
16. A retroviral particle obtainable from the retroviral vector of claim 9 or 15.
- Sub B3*
17. A retroviral particle obtainable from the retroviral vector of claim 9 or 15.
18. A cell transfected or transduced with a retroviral vector according to claim 9 or 15.
- A22*
19. A retroviral vector according to claim 9 or 15 for use in medicine.
20. Use of a retroviral vector according to claim 9 or 15 for the manufacture of a pharmaceutical composition to deliver an NOI to a target site in need of same.
- Sub C1*
21. A method comprising transfecting or transducing a cell with a retroviral vector according to claim 9 or 15.
22. A delivery system in the form of a retroviral vector according to claim 9 or 15.
23. A delivery system for a retroviral vector according to claim 9 or 15 wherein the delivery system comprises a non-retroviral expression vector, an adenovirus and/or a plasmid.

✓ Please cancel claims 1-8, 13 and 14 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, line 2, please insert -- This is a Divisional Application of allowed United States Patent Application No. 09/238,356, which is a Continuing Application of PCT/GB98/03876, filed December 22, 1998, claiming priority to United Kingdom Application